Akebia Therapeutics: Still Bullish On Vafseo As Auryxia's Revenues Decline
Akebia Therapeutics is currently shifting focus from Auryxia to Vafseo due to Auryxia’s declining revenues. See why I ...
INmune Bio's CORDStrom shows promise in RDEB treatment
BOCA RATON, FLORIDA - INmune Bio , Inc. (NASDAQ: NASDAQ:INMB), a clinical-stage biotechnology company with a market capitalization of $212.74 million, announced today its plans to submit regulatory ...
Sen-Jam Pharmaceutical Engages Destum Partners To Source Strategic Partnerships For SJP-001 ...
Sen-Jam Pharmaceutical, a pioneering biotech company dedicated to innovative anti-inflammatory solutions, is pleased to announce its engagement with Destum Partners, a leading advisory firm ...